Tech Company Financing Transactions
Agios Pharmaceuticals Funding Round
On 9/30/2009, Agios Pharmaceuticals announced $18 million in funding from Arch Venture Partners, Third Rock Ventures and private investors.
Transaction Overview
Company Name
Announced On
9/30/2009
Transaction Type
Venture Equity
Amount
$18,000,000
Round
Undisclosed
Investors
Arch Venture Partners (Robert Nelsen)
Third Rock Ventures (Kevin Starr)
Proceeds Purpose
Proceeds purposes were not disclosed.
Company Information
Company Status
Publicly-held
Industry
Biopharmaceutical
Mailing Address
88 Sidney St.
Cambridge, MA 02139
USA
Cambridge, MA 02139
USA
Phone
Website
Email Address
Overview
Agios (NASDAQ: AGIO) is a biopharmaceutical company at the forefront of one of the most exciting new areas of cancer research: cancer metabolism. Cancer metabolism represents a breakthrough understanding of how cancer cells become addicted to using more nutrients than normal cells to ensure their survival and growth.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Jacqualyn Fouse
Chief Financial Officer
Andrew Hirsch
Chief Medical Officer
Chris Bowden
Chief Scientific Officer
Scott Biller
VP - Human Resources
Melissa McLaughlin
VP - Marketing
Darrin Miles
VP - Operations
Clive Patience
Browse more venture capital transactions:
Prev: 9/30/2009: GridApp Systems venture capital transaction
Next: 9/30/2009: Veracyte venture capital transaction
Share this article
Where The Data Comes From
We do our best to report on every notable VC transaction. VC investment data records reported here are sourced from news reports and company announcements. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs